[Form 4] Astrana Health Inc. Insider Trading Activity

Rhea-AI Filing Summary

Basho Chandan, Astrana Health (ASTH) COO and CFO, reported a Form 4 disclosing a transaction on 09/05/2025 in which 1,694 shares of common stock were surrendered to cover tax withholding for vested restricted stock units at an effective price of $29.70 per share. After the surrender, the filing shows beneficial ownership of 176,946 shares.

The filing also details unvested restricted stock and restricted stock unit schedules: 7,214 shares vesting 4/14/2026; 30,404 shares vesting in two equal annual installments on 5/16/2026 and 5/16/2027; 23,404 RSUs vesting in six semi-annual installments beginning 10/02/2025; and 23,364 RSUs vesting in seven semi-annual installments beginning 03/05/2026. The transaction is coded F and represents a tax-withholding surrender, a routine insider action.

Positive

• Disclosure compliance: Form 4 filed, providing transparency on insider ownership changes
• Substantial remaining ownership: Reporting person retains 176,946 shares after the transaction
• Long-term alignment: Multiple unvested restricted stock and RSU tranches vesting through 2027 support retention incentives

Negative

• Minor reduction in issued shares due to surrender of 1,694 shares for tax withholding
• Potential dilution: Outstanding unvested awards will increase share count when they vest (schedules through 2027)

Insights

Financial Analyst

TL;DR: Routine share surrender to satisfy tax withholding; ownership largely intact with scheduled vesting over 2025–2027.

The reported F code transaction reflects surrender of 1,694 shares to cover taxes on vested RSUs at $29.70 per share. This is an administrative action rather than a sale for liquidity or diversification, leaving total beneficial ownership at 176,946 shares. The disclosed vesting schedule shows material incremental equity incentives through 2027, which aligns management compensation with future service and performance milestones. For investors, this is neutral in isolation but confirms ongoing equity retention by a senior officer.

Corporate Governance Expert

TL;DR: Filing indicates standard insider tax-withholding and continued alignment via multi-year vesting schedules.

The Form 4 documents a standard withholding mechanism following RSU vesting; the use of surrendered shares (not open-market sales) suggests no immediate intent to materially reduce insider stake. The detailed vesting timetables for both restricted stock and RSUs demonstrate continued retention incentives. From a governance perspective, this supports alignment between executive and shareholder interests and is not a red flag for governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Basho Chandan

(Last) (First) (Middle)

C/O ASTRANA HEALTH, INC.

1668 S. GARFIELD AVENUE, 2ND FLOOR

(Street)

ALHAMBRA CA 91801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Astrana Health, Inc. [ ASTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/05/2025		F		1,694(1)	D	$29.7	176,946(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the surrender of shares to offset against tax withholding obligations associated with certain restricted stock units that vested on September 5, 2025.

2. Includes the following shares of unvested restricted stock, which will vest as follows (in each case subject to continuous employment with the Issuer): (i) 7,214 shares, which will vest on April 14, 2026; and (ii) 30,404 shares, which will vest in two equal annual installments on May 16, 2026 and 2027. Also includes the following restricted stock units, which will vest as follows (in each case subject to continuous employment with the Issuer): (i) 23,404 restricted stock units, which will vest in six equal semi-annual installments beginning on October 2, 2025; and (ii) 23,364 restricted stock units, which will vest in seven equal semi-annual installments beginning on March 5, 2026.

	/s/ Kathy Diep, as Attorney-in-Fact	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ASTH insider Basho Chandan report on Form 4?

The Form 4 reports a 9/05/2025 transaction where 1,694 common shares were surrendered for tax withholding at $29.70 per share, leaving 176,946 shares beneficially owned.

Why were shares surrendered in the ASTH Form 4 filing?

The filing states the surrender represented tax withholding obligations associated with certain restricted stock units that vested on 9/05/2025.

How many unvested restricted shares and RSUs does the filing disclose?

The filing discloses: 7,214 shares vesting 4/14/2026; 30,404 shares vesting in two equal installments on 5/16/2026 and 5/16/2027; 23,404 RSUs vesting in six semi-annual installments starting 10/02/2025; and 23,364 RSUs vesting in seven semi-annual installments starting 03/05/2026.

Does the Form 4 indicate a sale of shares by the insider?

No. The transaction is coded F, indicating shares were surrendered to satisfy tax withholding on vested awards, not an open-market sale for cash.

Who filed the Form 4 for Basho Chandan?

The Form 4 is signed by Kathy Diep as Attorney-in-Fact on behalf of the reporting person, dated 09/09/2025.